SCHEMBL6752883

SCHEMBL6752883

CN=c1n(CC(=O)c2cc(C(C)(C)C)c(OC(=O)C(F)(F)F)c(C(C)(C)C)c2)c2ccccc2n1Cc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2R P25116 10/20 0.56
CXCR3 P49682 1/20 0.41
MAPT P10636 5/20 0.39
KMT2A Q03164 4/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
KDM4E B2RXH2 3/20 0.39
MEN1 O00255 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
LMNA P02545 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
ALDH1A1 P00352 1/20 0.37
MITF O75030 2/20 0.37
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 2/20 0.36
BCHE P06276 1/20 0.36
MAOA P21397 1/20 0.36
ACHE P22303 1/20 0.36
OXTR P30559 1/20 0.36
AVPR1A P37288 1/20 0.36
BLM P54132 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL6752882 0.86 F2R (0.70) F2RCXCR3MAPTKMT2ASMN1; SMN2
Trifluoroacetic Acid SCHEMBL6752886 0.86 F2R (0.70) F2RCXCR3MAPTKMT2ASMN1; SMN2
SCHEMBL6748424 0.84 F2R (0.64) F2RCXCR3MAPTKMT2ASMN1; SMN2
SCHEMBL6750404 0.83 F2R (0.66) F2RCXCR3MAPTKMT2ASMN1; SMN2
SCHEMBL6746329 0.82 F2R (0.61) F2RCXCR3MAPTKMT2ASMN1; SMN2
SCHEMBL4340442 0.77 F2R (0.50) F2RMAPTKMT2ASMN1; SMN2KDM4E
SCHEMBL4338978 0.76 F2R (0.49) F2RMAPTKMT2ASMN1; SMN2KDM4E
SCHEMBL6846941 0.75 F2R (0.78) F2RMAPTKMT2ASMN1; SMN2KDM4E
SCHEMBL4336031 0.75 F2R (0.39) F2RMAPTKMT2ASMN1; SMN2KDM4E
Bromide SCHEMBL6752696 0.75 F2R (0.70) F2RMAPTKMT2ASMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040242627-A1 2-Iminoimidazole derivatives (1) EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242627-A1 2-Iminoimidazole derivatives (1) H1-2, H1-0, H1-3 F2R 4027/4885CXCR3 3100/4885MAPT 4077/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.